CIPROFLOXACIN HYDROCHLORIDE

Post-LOE

ciprofloxacin hydrochloride

Novartis

ANDAORALTABLET

Approved

Mar 2004

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CIPROFLOXACIN HYDROCHLORIDE (ciprofloxacin hydrochloride) by Novartis is 12. Approved for plague, including pheumonic, septicemic plague and 38 more indications. First approved in 2004.

Drug data last refreshed 19h ago

Mechanism of Action

12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see ]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.…

Worked on CIPROFLOXACIN HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

CIPROFLOXACIN HYDROCHLORIDE

Mechanism of Action

Indications (39)